Kailera Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-148.96	-329.57
Depreciation & Amortization	0.31	0.08
Loss (Gain) From Sale of Investments	-1.73	-
Stock-Based Compensation	10.94	1.41
Other Operating Activities	2.44	139.5
Change in Accounts Payable	4.69	3.01
Change in Other Net Operating Assets	12.09	0.61
Operating Cash Flow	-120.21	-184.95
Capital Expenditures	-2.09	-0.39
Investment in Securities	-490.51	-
Investing Cash Flow	-492.6	-0.39
Long-Term Debt Issued	100	-
Net Debt Issued (Repaid)	100	-
Issuance of Common Stock	0.1	-
Other Financing Activities	-0.32	-
Financing Cash Flow	598.66	448.11
Net Cash Flow	-14.15	262.77
Free Cash Flow	-122.3	-185.35
Free Cash Flow Per Share	-6420.52	-
Levered Free Cash Flow	-59.89	-
Unlevered Free Cash Flow	-59.89	-
Change in Working Capital	16.78	3.62

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q